Novavax COVID-19 vaccine, also known as Nuvaxovid, has been provisionally approved by the Therapeutic Goods Administration for use in a primary course of vaccination in people aged 18 years and older.
Following this approval, the Australian Technical Advisory Group on Immunisation (ATAGI) has published recommendations on the use of Nuvaxovid.
In addition, the Australian Government Department of Health has published new Nuvaxovid fact sheets for immunisation providers and patients.
For more information on COVID-19 vaccines, visit the Department of Health.

